BiondVax Pharmaceuticals Ltd.
BVXV · NASDAQ
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$0 | -$0 | -$0 | $0 |
| % Margin | – | – | – | – |
| Net Income | -$0 | -$0 | $0 | $0 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.11 | -1.19 | -1.76 | 5.24 |
| % Growth | 6.7% | 32.4% | -133.6% | – |
| Operating Cash Flow | -$0 | -$0 | $0 | – |
| Capital Expenditures | -$0 | -$0 | -$0 | – |
| Free Cash Flow | -$0 | -$0 | $0 | – |